文献速递白血病

慢性期慢性髓性白血病常规临床实践中的一线治疗选择与早期监测模式:SIMPLICITY研究

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
PubMed 文献 · Am J Hematol · 2017-09-25

SIMPLICITY是一项观察性研究,纳入美国及6个欧洲国家1242例接受一线伊马替尼(416例)、达沙替尼(418例)或尼洛替尼(408例)的慢性期慢性髓性白血病患者,报告12个月随访数据。治疗选择基于感知疗效而非合并症。3、6、12个月细胞遗传学/分子学监测记录率分别为36%、82%、95%,5%患者第一年无监测记录。研究表明NCCN和ELN的监测推荐未一致转化为常规实践。

要点

  • 3、6、12个月细胞遗传学/分子学监测记录率分别为36%、82%、95%,5%患者第一年无监测记录。
  • 欧洲监测记录率高于美国(P < .001),学术机构高于社区机构(P = .001)。
  • 治疗选择基于感知疗效而非患者合并症,81%患者有基线合并症。

核心结论

  • SIMPLICITY表明NCCN和ELN关于反应监测的推荐未一致转化为常规临床实践。
  • 缺乏适当监测实践时,无法确立TKI治疗的临床反应,任何所需的治疗策略调整将无法实施,可能影响长期患者结局。

研究设计与样本

  • SIMPLICITY(NCT01244750)是一项观察性研究,探索美国及6个欧洲国家常规临床实践中慢性期慢性髓性白血病患者的一线TKI使用与管理模式。
  • 纳入接受一线伊马替尼(n = 416)、达沙替尼(n = 418)或尼洛替尼(n = 408)的患者,报告1242例前瞻性患者(入组时间2010年10月1日至2015年9月2日)的12个月随访数据。

主要发现

  • 81%的患者有基线合并症,治疗选择基于感知疗效而非患者合并症特征。
  • 研究早期入组患者以伊马替尼治疗为主,至2013/2014年逐渐转向达沙替尼和尼洛替尼治疗。
  • 细胞遗传学/分子学监测记录率随时间改善,3、6、12个月分别有36%、82%、95%的患者有记录;5%的患者在治疗第一年无细胞遗传学/分子学监测记录。
  • 欧洲的分子学/细胞遗传学检测记录率高于美国(P < .001),学术机构高于社区机构(P = .001)。
  • 年龄<65岁、在欧洲站点随访、在学术中心随访以及不再接受一线治疗的患者更可能在12个月时接受监测。

临床怎么用

  • 原文未据此给出推荐。
  • SIMPLICITY表明NCCN和ELN关于反应监测的推荐未一致转化为常规临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Achieving successful outcomes in chronic phase-chronic myeloid leukemia (CP-CML) requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor use and management patterns in patients with CP-CML receiving first-line imatinib (n = 416), dasatinib (n = 418) or nilotinib (n = 408) in the US and 6 European countries in routine clinical practice. Twelve-month follow-up data of 1242 prospective patients (enrolled October 01 2010-September 02 2015) are reported. 81% of patients had baseline comorbidities. Treatment selection was based on perceived efficacy over patient comorbidity profile. There was a predominance of imatinib-treated patients enrolled earlier in the study, with subsequent shift toward dasatinib- and nilotinib-treated patients by 2013/2014. Monitoring for either CyR/MR improved over time and was documented for 36%, 82%, and 95% of patients by 3, 6, and 12 months, respectively; 5% had no documentation of CyR/MR monitoring during the first year of therapy. Documentation of MR/CyR testing was higher in Europe than the US (P < .001) and at academic versus community practices (P = .001). Age <65 years, patients being followed at sites within Europe, those followed at academic centers and patients no longer on first-line therapy were more likely to be monitored by 12 months. SIMPLICITY demonstrates that the NCCN and ELN recommendations on response monitoring have not been consistently translated into routine clinical practice. In the absence of appropriate monitoring practices, clinical response to TKI therapy cannot be established, any needed changes to treatment strategy will thus not be implemented, and long-term patient outcomes are likely to be impacted.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Goldberg SL, Cortes JE, Gambacorti-Passerini C, et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017. PMID: 28815757. doi:10.1002/ajh.24887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。